This is great news for Merck regarding their new HDL-boosting-LDL-busting drug Anacetrapib. Published about a week ago:
Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease
Quote: "The prespecified Bayesian analysis indicated that this event distribution provided a predictive probability (confidence) of 94% that anacetrapib would not be associated with a 25% increase in cardiovascular events, as seen with torcetrapib."
See also this:
Merck’s Risky Bet on Heart Drugs May Yield Lipitor-Like Success
Interestingly, the company's stock declined by about 5% in November to date.
Just a little on complex I and models - OK, just a brief summary of the parts I like most from the excellent The CoQH2/CoQ Ratio Serves as a Sensor of Respiratory Chain Efficiency. We should all ...
1 hour ago